Literature DB >> 3396264

Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.

S Kawasaki1, Y Sugiyama, T Iga, M Hanano, T Beppu, M Sugiura, K Sanjo, Y Idezuki.   

Abstract

Blood clearance of antipyrine, indocyanine green, and galactose were measured to evaluate the alterations of effective hepatic blood flow and hepatic intrinsic clearances in chronic liver diseases. Galactose blood clearance, which may be taken as effective hepatic blood flow, decreased by approximately 30% in patients with cirrhosis (12.49 +/- 0.76 ml/min/kg; mean +/- SE; n = 17) compared with normal subjects (18.17 +/- 1.03 ml/min/kg; n = 5). In patients with cirrhosis, intrinsic clearances of antipyrine (0.178 +/- 0.014 ml/min/kg; n = 17) and indocyanine green (6.19 +/- 1.38 ml/min/kg; n = 7) showed 61% and 85% reduction, respectively, compared with those of normal subjects (0.462 +/- 0.048 ml/min/kg; n = 5; 41.72 +/- 7.75 ml/min/kg; n = 5). Considering that indocyanine green and antipyrine are eliminated by different hepatic mechanism, these mechanisms may not be equally sensitive to decrements in hepatic function. In addition, fractional reductions of intrinsic clearances for these compounds are thus much greater than that of effective hepatic blood flow.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3396264     DOI: 10.1038/clpt.1988.140

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

Review 1.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

Review 2.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

3.  The effect of roxatidine acetate and cimetidine on hepatic drug clearance assessed by simultaneous administration of three model substrates.

Authors:  E Tanaka; K Nakamura
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

4.  Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.

Authors:  W L Hayton; J Kneer; R A Blouin; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

5.  The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans.

Authors:  T Lavé; S Dupin; C Schmitt; B Valles; G Ubeaud; R C Chou; D Jaeck; P Coassolo
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

Review 6.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

Review 7.  Noninvasive assessment of liver function.

Authors:  Steve Helmke; Jordi Colmenero; Gregory T Everson
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

Review 8.  Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update.

Authors:  D J Morgan; A J McLean
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

9.  Surgical Strategy Based on Indocyanine Green Test for Chemotherapy-Associated Liver Injury and Long-Term Outcome in Colorectal Liver Metastases.

Authors:  Takeshi Takamoto; Takuya Hashimoto; Akihiko Ichida; Kei Shimada; Yoshikazu Maruyama; Masatoshi Makuuchi
Journal:  J Gastrointest Surg       Date:  2018-02-27       Impact factor: 3.452

10.  Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.

Authors:  Kenneth C Lasseter; Stacy C Dilzer; Ramon Vargas; Scott Waldman; Robert J Noveck
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.